HIV与性腺功能减退：对抗逆转录病毒疗法有效的中青年男性面临的新挑战。
HIV and hypogonadism: a new challenge for young-aged and middle-aged men on effective antiretroviral therapy.
作者信息
Lachâtre Marie, Pasquet Armelle, Ajana Faïza, Soudan Benoit, Lion Georges, Bocket Laurence, Cornavin Pauline, Senneville Eric, Boufassa Faroudy, Chéret Antoine
机构信息
aDepartment of Infectious Diseases, Bichat-Claude-Bernard Hospital, AP-HPbParis Diderot University, Sorbonne Paris Cité, PariscDepartment of Infectious Diseases, Tourcoing Hospital, TourcoingdLaboratory of Biochemistry, Lille Hospital, LilleeDepartment of Nuclear Medicine, Lille Hospital, LillefLaboratory of Virology, Lille Hospital, LillegParis-Saclay University, Paris-Sud University, UVSQ, CESP U1018, INSERMhDepartment of Internal Medicine, Bicêtre Hospital, AP-HPiEA 7327 Paris Descartes University, Paris, France.
出版信息
AIDS. 2017 Jan 28;31(3):451-453. doi: 10.1097/QAD.0000000000001348.
Male hypogonadism is poorly defined in people living with HIV. Using a reliable free-testosterone assay, we examined the prevalence and risk factors of male hypogonadism among people living with HIV on effective antiretroviral therapy. Male hypogonadism was found in 12.4% of patients, twice the rate reported in the general population of the same age. Two risk thresholds, namely 5 years of antiretroviral therapy and 19% total body fat, may help to identify patients at risk.
男性性腺功能减退在HIV感染者中定义不明确。我们使用可靠的游离睾酮检测方法，研究了接受有效抗逆转录病毒治疗的HIV感染者中男性性腺功能减退的患病率和危险因素。在12.4%的患者中发现了男性性腺功能减退，这一比例是同年龄普通人群报告率的两倍。两个风险阈值，即5年的抗逆转录病毒治疗和19%的体脂率，可能有助于识别有风险的患者。
Zotero 插件